Why the study?
Patients with cancer and cardiovascular disease are particularly vulnerable during the COVID-19 pandemic, requiring evaluation of the pandemic's impact to optimize medical strategies during and after the emergency.
Provides essential expert consensus guidance for adapting cardio-oncology care pathways during the COVID-19 pandemic to protect vulnerable cancer patients.
Answers are grounded in this paper and cite their sources.
Requires urgent implementation of remote monitoring in cardio-oncology during pandemics; extends consensus guidance to protect vulnerable patients.
The COVID-19 pandemic and its impact on patients with cancer and cardiovascular disease have confirmed the particular vulnerability of these populations. Indeed, not only a higher risk of contracting the infection has been reported but also an increased occurrence of a more severe course and unfavourable outcome. Beyond the direct consequences of COVID-19 infection, the pandemic has an enormous impact on global health systems. Screening programmes and non-urgent tests have been postponed; clinical trials have suffered a setback. Similarly, in the area of cardiology care, a significant decline in STEMI accesses and an increase in cases of late presenting heart attacks with increased mortality and complication rates have been reported. Health care systems must therefore get ready to tackle the 'rebound effect' that will likely show a relative increase in the short- and medium-term incidence of diseases such as heart failure, myocardial infarction, arrhythmias, and cardio- and cerebrovascular complications. Scientific societies are taking action to provide general guidance and recommendations aimed at mitigating the unfavourable outcomes of this pandemic emergency. Cardio-oncology, as an emerging discipline, is more flexible in modulating care pathways and represents a beacon of innovation in the development of multi-specialty patient management. In the era of the COVID-19 pandemic, cardio-oncology has rapidly modified its clinical care pathways and implemented flexible monitoring protocols that include targeted use of cardiac imaging, increased use of biomarkers, and telemedicine systems. The goal of these strategic adjustments is to minimize the risk of infection for providers and patients while maintaining standards of care for the treatment of oncologic and cardiovascular diseases. The aim of this document is to evaluate the impact of the pandemic on the management of cardio-oncologic patients with the-state-of-the-art knowledge about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease (COVID-19) in order to optimize medical strategies during and after the pandemic.
No takes yet. Share an insight, caveat, or question.
Bisceglia et al. (2021) conducted a review in Cancer and cardiovascular disease during the COVID-19 pandemic. Modified clinical care pathways (telemedicine, targeted cardiac imaging, biomarker surveillance) was evaluated. Cardio-oncology care pathways must be rapidly modified during the COVID-19 pandemic by implementing telemedicine, targeted cardiac imaging, and biomarker surveillance to minimize infection risk.
Synapse has enriched 10 related papers. Consider them for comparative context: